Actively Recruiting
BAL Fluid Biomarkers in Sarcoma
Led by University Health Network, Toronto · Updated on 2026-03-04
70
Participants Needed
1
Research Sites
374 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
CONDITIONS
Official Title
BAL Fluid Biomarkers in Sarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Ability to understand and willing to sign a written informed consent document
- Diagnosed with soft tissue sarcoma
- Undergoing resection of lung lesion as part of standard care
You will not qualify if you...
- History of another invasive malignancy except non-melanoma skin cancer or tumors treated with no evidence of disease for 2 years or more
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
D
David Shultz
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here